{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:00Z","timestamp":1761541140609,"version":"3.44.0"},"reference-count":43,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart"],"accepted":{"date-parts":[[2012,10,9]]},"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Amlodipine inhibits cytochrome P450 (CYP) enzyme and has the potential to reduce clopidogrel bioactivation in vivo. Reports in previous retrospective studies described greater platelet reactivity in patients on amlodipine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the treatment effect of clopidogrel in patients on amlodipine versus not on calcium-channel blockers (CCBs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and setting<\/jats:title>\n                  <jats:p>Randomised, controlled, open-label trial conducted in a regional acute hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and interventions<\/jats:title>\n                  <jats:p>98 patients on clopidogrel for ischaemic heart disease were recruited consecutively and randomised to take either amlodipine or drugs with inert CYP effects as controls. The P2Y12 reaction unit (PRU) was measured using whole blood obtained at baseline and on day 28.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>The primary analysis involved the PRU values on day 28. The secondary analyses were percentage of platelet inhibition and poor response to clopidogrel as defined by PRU&gt;235.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Both groups experienced comparable day 28 PRUs (amlodipine 227\u00b184 vs control 214\u00b190; mean difference 12.7, 95% CI \u221222 to +47). Percentage of platelet inhibition (amlodipine 33% vs control 38%, mean difference \u22124.5%, 95% CI \u221214% to +5%) and those with poor response on day 28 (amlodipine 49% vs control 45%; p=0.76) did not differ significantly.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Concomitant amlodipine has no negative impact on clopidogrel-mediated platelet inhibition in patients with ischaemic heart disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2012-302801","type":"journal-article","created":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T20:19:43Z","timestamp":1351801183000},"page":"468-473","source":"Crossref","is-referenced-by-count":15,"title":["Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: a randomised, controlled trial"],"prefix":"10.1136","volume":"99","clinical-trial-number":[{"clinical-trial-number":"nct01203696","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrew Y W","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fook-Hong","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis K L","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine & Therapeutics, the Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabowo","family":"Tunggal","sequence":"additional","affiliation":[{"name":"Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kit","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuk-Kong","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2012,10,31]]},"reference":[{"key":"2025092000313636000_99.7.468.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00496-2"},{"key":"2025092000313636000_99.7.468.2","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.82.6.1954","article-title":"A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure","volume":"82","author":"Elkayam","year":"1990","journal-title":"Circulation"},{"key":"2025092000313636000_99.7.468.3","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029132"},{"key":"2025092000313636000_99.7.468.4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH06-08-0420","article-title":"Thienopyridines in cardiovascular disease: focus on clopidogrel resistance","volume":"97","author":"Siller-Matula","year":"2007","journal-title":"Thromb Haemost"},{"key":"2025092000313636000_99.7.468.5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1160\/TH09-08-0516","article-title":"The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response","volume":"103","author":"Harmsze","year":"2010","journal-title":"Thromb Haemost"},{"key":"2025092000313636000_99.7.468.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.07.055"},{"key":"2025092000313636000_99.7.468.7","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.171488"},{"key":"2025092000313636000_99.7.468.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.11.010"},{"key":"2025092000313636000_99.7.468.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.08.640"},{"key":"2025092000313636000_99.7.468.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.111.963405"},{"key":"2025092000313636000_99.7.468.11","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835050-00003"},{"key":"2025092000313636000_99.7.468.12","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050706"},{"key":"2025092000313636000_99.7.468.13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0090-9556(24)15118-5","article-title":"Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A","volume":"28","author":"Ma","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"2025092000313636000_99.7.468.14","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31815c16f5"},{"key":"2025092000313636000_99.7.468.15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199222060-00002","article-title":"Clinical pharmacokinetics of calcium antagonists: An update","volume":"22","author":"Kelly","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"2025092000313636000_99.7.468.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03733.x"},{"key":"2025092000313636000_99.7.468.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.047"},{"key":"2025092000313636000_99.7.468.18","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-01-0040"},{"key":"2025092000313636000_99.7.468.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.812636"},{"key":"2025092000313636000_99.7.468.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.054"},{"key":"2025092000313636000_99.7.468.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.833236"},{"key":"2025092000313636000_99.7.468.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.06.038"},{"key":"2025092000313636000_99.7.468.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.181"},{"key":"2025092000313636000_99.7.468.24","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2006.28.5.990205"},{"key":"2025092000313636000_99.7.468.25","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.100891"},{"key":"2025092000313636000_99.7.468.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.05.054"},{"key":"2025092000313636000_99.7.468.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.038"},{"key":"2025092000313636000_99.7.468.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-8727(00)00132-X"},{"key":"2025092000313636000_99.7.468.29","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000199519.37089.a0"},{"key":"2025092000313636000_99.7.468.30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0038-1646320","article-title":"Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins","volume":"68","author":"Winocour","year":"1992","journal-title":"Thromb Haemost"},{"key":"2025092000313636000_99.7.468.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"2025092000313636000_99.7.468.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.11.030"},{"key":"2025092000313636000_99.7.468.33","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"},{"key":"2025092000313636000_99.7.468.34","unstructured":"Food and Drug Administration. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. FDA drug safety communication. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203888.htm ."},{"key":"2025092000313636000_99.7.468.35","doi-asserted-by":"publisher","DOI":"10.2174\/138920008785821710"},{"key":"2025092000313636000_99.7.468.36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010173200"},{"key":"2025092000313636000_99.7.468.37","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.620"},{"key":"2025092000313636000_99.7.468.38","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.3.737"},{"key":"2025092000313636000_99.7.468.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0092-9"},{"key":"2025092000313636000_99.7.468.40","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200107000-00004"},{"key":"2025092000313636000_99.7.468.41","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9083-5"},{"key":"2025092000313636000_99.7.468.42","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.220509"},{"key":"2025092000313636000_99.7.468.43","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1016\/S0021-9258(18)68458-3","article-title":"Cytochrome P-450-catalyzed hydroxylation and carboxylic acid ester cleavage of hantzsch pyridine esters","volume":"263","author":"Guengerich","year":"1988","journal-title":"J Biol Chem"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2012-302801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T07:31:46Z","timestamp":1758353506000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2012-302801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,31]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,3,6]]},"published-print":{"date-parts":[[2013,4,1]]}},"alternative-id":["10.1136\/heartjnl-2012-302801"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2012-302801","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[2012,10,31]]}}}